Maria V. Muzalevskaya

Maria V. Muzalevskaya

Auto-generated profile, based on publicly available information

Maria V. Muzalevskaya

Department of Pathology, Laboratory of the Microangiopathic Mechanisms of Atherogenesis, Saint Petersburg State University, Saint Petersburg 199034, Russia; L.G. Sokolov North-Western District Scientific and Clinical Centre, Saint Petersburg 194291, Russia

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 June 2019 in Russian Journal of Cardiology
Verified
Journal Article
Open access
PDF file
MYM. V. Yezhov
M. V. Yezhov
SBS. A. Bliznyuk
S. A. Bliznyuk
NTNarek Tmoyan
Narek Tmoyan
TRT. A. Rozhkova
T. A. Rozhkova
Dmitry V. DuplyakovDmitry V. Duplyakov
Dmitry V. Duplyakov
ТКТ. Ю. Кузнецова
Т. Ю. Кузнецова
Регистр пациентов с семейной гиперхолестеринемией и пациентов очень высокого сердечно-сосудистого риска с недостаточной эффективностью проводимой гиполипидемической терапии (РЕНЕССАНС)

24 April 2023 in Russian Cardiology Bulletin
Verified
Journal Article
Closed access
Uliana V ChubykinaUliana V Chubykina
Uliana V Chubykina
Marat EzhovMarat Ezhov
Marat Ezhov
TRT.A. Rozhkova
T.A. Rozhkova
BTB.M. Tamaeva
B.M. Tamaeva
ASA.A. Sokolov
A.A. Sokolov
SBS.E. Bednova
S.E. Bednova
ЦЕЛЬ ИССЛЕДОВАНИЯ Оценить комплаентность пациентов с гетерозиготной семейной гиперхолестеринемией (геСГХС) в течение 5-летнего периода работы регистра РЕНЕССАНС (Регистр пациентов с СГХС и пациентов очень высокого сЕрдечно-Сосудистого риска с недоСтАточной эффективНоСтью, проводимой гиполипидемической терапии). МАТЕРИАЛ И МЕТОДЫ РЕНЕССАНС является открытым, национальным, наблюдательным исследованием и включает больных с СГХС. Проводилась оценка факторов риска атеросклероза, анамнеза сердечно-сосудистых заболеваний (ССЗ), интенсивности гиполипидемической терапии (ГЛТ). Каждому пациенту определены уровни общего холестерина, триглицеридов, холестерина липопротеидов высокой плотности в сыворотке крови. Содержание холестерина липопротеидов низкой плотности (ХС ЛНП) рассчитывали по формуле Фридвальда. РЕЗУЛЬТАТЫ В исследование включено 2317 пациентов с геСГХС, из которых 58% — женщин. При включении в регистр 59% больных относились к категории высокого сердечно-сосудистого риска. Динамический визит проведен у 47% пациентов, период наблюдения составил 24 [11; 42] мес. Больные с динамическим визитом чаще имели определенный диагноз геСГХС и отягощенный наследственный анамнез по ССЗ, были моложе и им в более раннем возрасте диагностировали СГХС (p<0,05). У пациентов без динамического визита были распространены модифицируемые факторы риска (p<0,001). Среди пациентов высокого сердечно-сосудистого риска 54% больных получали ГЛТ, очень высокого — 86%. За время наблюдения в регистре доля принимающих ГЛТ пациентов увеличилась с 59 до 78%, в том числе статинами в режиме высокой интенсивности с 36 до 54%, в комбинации с эзетимибом — с 15 до 34%, ингибиторами PCSK9 — с 4 до 14% (p<0,001 для всех). Целевого уровня ХС ЛНП достигли 13% пациентов. Данные симуляционного анализа продемонстрировали, что для адекватного контроля уровня ХС ЛНП, не менее 92,5% больных с геСГХС в регистре должны получать трехкомпонентную ГЛТ со статинами, эзетимибом и ингибиторами PCSK9. ЗАКЛЮЧЕНИЕ 5-летнее наблюдение за участниками регистра РЕНЕССАНС демонстрирует увеличение использования многокомпонентных схем лечения, но недостаточное для адекватного контроля ХС ЛНП.

21 November 2025 in Russian Journal of Cardiology
Verified
Journal Article
Closed access
VMValentina V. Miroshnikova
Valentina V. Miroshnikova
AIArtem Dmitrievich Izyumchenko
Artem Dmitrievich Izyumchenko
MMM. V. Muzalevskaya
M. V. Muzalevskaya
KLK. V. Legostaeva
K. V. Legostaeva
MGMaria Grunina
Maria Grunina
SPSofia Pchelina
Sofia Pchelina
Aim. To determine the frequency of pathogenic and likely pathogenic variants associated with familial hypercholesterolemia (FH) with assessment of the proportion of polygenic FH according to the 6-SNP genetic risk score (GRS) among patients diagnosed with possible/probable/definite FH in St. Petersburg. Material and methods. This study tested a hybrid targeted panel for gene diagnostics of hereditary dyslipidemias, including an expanded list of genes associated with monogenic dyslipidemias and a number of single-nucleotide variants associated with polygenic hypercholesterolemia and cardiovascular risk. Genetic testing was performed on 125 patients. Results. A total of 26 pathogenic and likely pathogenic variants in the LDLR gene were identified in 38 patients, while 6 variants of uncertain clinical significance in the LDLR gene — in 7 patients, and a pathogenic variant 10580G>A (p.Arg3527G) in the APOB gene — in 6 patients. The highest detection rate of causal genetic variants (66,7%) was observed, as expected, in the subgroup of patients with definite FH. Patients with a high polygenic risk of hypercholesterolemia predominated in the subgroups diagnosed with possible and probable FH. Conclusion. The use of an expanded next-generation sequencing (NGS) panel, including genes for hereditary dyslipidemias, as well as loci for calculating the GRS, may be critical for differential diagnosis, determining the etiology of hypercholesterolemia, and personalizing treatment approaches.

22 August 2025 in Rational Pharmacotherapy in Cardiology
Verified
Journal Article
Open access
PDF file
IAI Alekseeva
I Alekseeva
Uliana V ChubykinaUliana V Chubykina
Uliana V Chubykina
Marat EzhovMarat Ezhov
Marat Ezhov
ATA Tyurina
A Tyurina
TKT Kolmakova
T Kolmakova
NBN Bizyaeva
N Bizyaeva
Aim. To study the adequacy and effectiveness of lipid-lowering therapy (LLT) prescribed to patients with heterozygous familial hypercholesterolemia (HeFH), including fixed-dose combinations (FDC) of rosuvastatin with ezetimibe, as well as the frequency of achieving target low-density lipoprotein cholesterol (LDL-C) levels.Material and methods. The clinical and demographic data of 3151 patients with HeFH at high or very high cardiovascular risk from the RENAISSANCE registry were retrospectively analysed. Among the 1612 individuals receiving LLT, 477 patients were treated with a combination of rosuvastatin at various doses and ezetimibe 10 mg daily, either as a free combination or as a FDC.Results. The median age of the patients was 46.0 [32.0; 57.0] years. The median LDL-C level was 6.4 [5.3; 7.8] mmol/L. Although LLT was recommended to all participants, approximately half (49%, n=1539) were not receiving treatment. Among the 1612 patients on LLT, 44% (n=703) received statin monotherapy, and 43% (n=697) were treated with a combination of statins and ezetimibe. Of the 477 patients taking rosuvastatin with ezetimibe, the majority were active adults of working age (35-64 years): 335 (80%) vs 86 (20%), p <0.05. Most patients preferred taking rosuvastatin with ezetimibe in the FDC: 357 (74.8%) vs 120 (25.2%), p <0.05. Among those on FDC, a significantly higher proportion used Zenon® compared to other FDCs: 44.4% (n=212) vs 30.4% (n=145), p <0.05. A significant reduction in LDL-C was observed compared to baseline: 61% in the free combination group and 65% in the FDC group, including a 67% reduction in the Zenon® subgroup (p <0.001). The rate of achieving LDL-C targets among high/very high cardiovascular risk patients was lower in the free combination group compared to the FDC group, with the highest rates observed among Zenon® users: 5.8% (n=7), 17.9% (n=26), and 21.7% (n=46), respectively (p <0.01).Conclusion. Among patients with НeFH, the use of a FDC of rosuvastatin and ezetimibe is associated with higher treatment adherence and a greater likelihood of achieving target LDL-С levels.

1 July 2026 in Exploration of Immunology
Verified
Journal Article
Open access
PDF file
Leonid ChurilovLeonid Churilov
Leonid Churilov
VGVictor S. Gurevich
Victor S. Gurevich
MMMaria V. Muzalevskaya
Maria V. Muzalevskaya
TNTatiana A. Novitskaya
Tatiana A. Novitskaya
VSValeriia A. Shapkina
Valeriia A. Shapkina
Muslimbek G. NormatovMuslimbek G. Normatov
Muslimbek G. Normatov
Aim: This study explores the pathogenesis of atherosclerosis, as well as the comorbidity of atherosclerosis and coronavirus infection. The objective of the article is to provide a rationale for the potential involvement of an autoimmune component in the observed comorbidity between these two conditions. Methods: The research utilized bioinformatic and laboratory techniques. The bioinformatic approach involved selecting 30 human autoantigens, either proven or hypothesized to participate in atherogenesis and/or arteritides, as well as the most immunogenic proteins from human coronavirus antigens. To identify shared minimal immunogenic determinants (pentapeptides) between human autoantigens and coronavirus antigens, the proprietary “Alignmentaj” program was employed. Antibody levels against apolipoprotein B-100 (ApoB-100) and Proteinase 3 (PR3) were measured using enzyme-linked immunosorbent assay (ELISA) in patients with cardiovascular disease following coronavirus disease 2019 (COVID-19). Post-mortem tissue samples were subjected to standard morphological examination, supplemented with immunohistochemical methods for pathomorphological analysis. Results: The analysis revealed that the spike protein of human coronaviruses exhibits the highest concentration of pentapeptides similar to those found in atherogenesis-associated proteins. Notably, ApoB-100 shared the greatest number of peptides. Post-COVID cardiovascular patients showed varied anti-ApoB antibody and anti-PR3 antibody levels and potential complications. Pathomorphological examination of the aorta and coronary arteries of patients who died from atherothrombotic complications following COVID-19 infection revealed signs of autoimmune inflammation. Lymphocytic infiltration, consisting of T-cells and B-cells, as well as indications of vasa vasorum vasculitis, were observed in areas of unstable aortic atherosclerotic plaques and in the adventitia of coronary arteries. Conclusions: The identified sequence homology between human coronavirus antigens and human autoantigens, together with laboratory data obtained from patients with cardiovascular pathology following COVID-19, supports the hypothesis that molecular mimicry contributes to the initiation or exacerbation of atherosclerotic cardiovascular disease in the post-COVID period.